Neuroprotective effects of creatine in a transgenic Mouse model of Huntington's disease

Journal of Neuroscience

Volumn 20, Issue 12, 2000, Pages 4389-4397

  Ferrante, Robert J ^a,b   Andreassen, Ole A ^c,d   Jenkins, Bruce G ^c,d   Dedeoglu, Alpaslan ^c,d   Kuemmerle, Stefan ^b   Kubilus, James K ^a,b   Kaddurah Daouk, Rima ^e   Hersch, Steven M ^f   Beal, M Flint ^c,d,g,h  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Avicena Group Inc   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Creatine; Diabetes; Huntington's disease; Mitochondria; N acetylaspartate; Transgenic mice

Indexed keywords

CREATINE; HUNTINGTIN; N ACETYLASPARTIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; HUNTINGTON CHOREA; MITOCHONDRION; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SURVIVAL; TRANSGENIC MOUSE;

EID: 0034660457     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.20-12-04389.2000     Document Type: Article

References (59)

1. Balsom PD, Soderlund K, Ekhlom B (1994) Creatine in humans with special reference to creatine supplementation. Sports Med 18:268-280.
2. 1H MRS studies in vivo. NeuroReport 7:1397-1400.
3. Bernardi P, Basso E, Colonna R, Costantini P, Di Lisa F, Eriksson O, Fontaine E, Forte M, Ichas F, Massari S, Nicolli A, Petronilli V, Scorrano L (1998) Perspectives of the mitochondrial permeability transition. Biochim Biophys Acta 1365:200-206.
4. Bogdanov MB, Ferrante RJ, Kuemmerle S, Klivenyi P, Beal MF (1998) Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. J Neurochcm 71:2652-2644.
5. Bottomley PA (1987) Spatial localization in NMR spectroscopy in vivo. Ann NY Acad Sci 508:333-348.
6. Brdiczka D, Beutner G, Ruck A, Dolder M, Wallimann T (1998) The molecular structure of mitochondrial contact sites. Their role in regulation of energy metabolism and permeability transition. Biofactors 8:235-242.
7. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 92:7105-7109.
8. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MMK, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646-653.
9. Carter AJ, Muller RE, Pschorn U, Stransky W (1995) Preincubation with creatine enhances levels of creatine phosphate and prevents anoxic damage in rat hippocampal slices. J Neurochem 64:2691-2699.
10. Cha J-HJ, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci USA 95:6480-6485.
11. 31P NMR magnetization transfer. J Cereb Blood Flow Metab 14:1070-1077.
12. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiari L, Bates GP (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537-548.
13. Dawson TM, Hung K, Dawson VL, Steiner JP, Snyder SH (1995) Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. Ann Neurol 37:115-118.
14. 2+ exchanger. Exp Neurol 145:38-45.
15. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993.
16. Dunant Y, Loctin F, Marsal J, Muller D, Parducz A, Rabasseda X (1988) Energy metabolism and quantal acetylcholine release: effects of botulinum toxin, 1-fluoro-2,4-dinitrobenzene, and diamide in the Torpedo electric organ. J Neurochem 50:431-439.
17. Ferrante RJ, Gutekunst CA, Persichetti F, McNeil SM, Kowall NW, Gusella JF, MacDonald ME, Beal MF, Hersch SM (1997) Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J Neurosci 17:3052-3063.
18. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. New York: Academic.
19. Greenhaff PL (1997) The nutritional biochemistry of creatine. J Nutr Biochem 8:610-618.
20. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AHV (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39:385-389.
21. Gutekunst C-A, Peng T-I, Whaley WL, Rock B, Hersch SM, Greenamyre JT (1996) Mitochondrial calcium homeostasis in Huntington's disease fibroblasts. Soc Neurosci Abstr 22:227.
22. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19:2522-2534.
23. Hemmer W, Wallimann T (1993) Functional aspects of creatine kinase in brain. Dev Neurosci 15:249-260.
24. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23:181-192.
25. Hurlbert MS, Zhou W, Wasmeier C, Kaddis FG, Hutton JC, Freed CR (1999) Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48:649-651.
26. Jenkins B, Koroshetz W, Beal MF, Rosen B (1993) Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy. Neurology 43:2689-2695.
27. Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, MacDonald M, Rosen BR, Beal MF, Koroshetz WJ (1998) 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 50:1357-1365.
28. Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal MF (2000) Non-linear decrease over time in N-acetylaspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem 74:2108-2119.
29. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wcrmer M, Kaddurah-Daouk R, Beal MF (1999) Neuroprotective effects of creatine in a transgenic animal model of ALS. Nat Med 5:347-350.
30. 10. Ann Neurol 41:160-165.
31. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ (1999) Huntingtin aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 46:842-849.
32. Landwehrmeyer GB, McNeil SM, Dure I, LS, Ge P, Aizawa H, Huang Q, Ambrose CM, Duyao MP, Bird ED, Bonilla E, de Young M, Avila-Gonzales AJ, Wexler NS, DiFiglia M, Gusella JF, MacDonald ME, Penney JB, Young AB, Vonsattel J-P (1995) Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals. Ann Neurol 37:218-230.
33. Leist M, Nicotera P (1998) Apoptosis, excitotoxicity, and neuropathology. Exp Cell Res 239:183-201.
34. Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES, Carpenter EM, Zanjani H, Hurst RS, Efstratiadis A, Zeitlin S, Chesselet MF (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 58:515-532.
35. Lipton SA, Nicotera P (1998) Excitotoxicity, free radicals, necrosis, and apoptosis. Neuroscientist 4:345-352.
36. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506.
37. Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF (1998) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 18:156-163.
38. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157:142-149.
39. O'Gorman E, Beutner G, Wallimann T, Brdiczka D (1996) Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. Biochim Biophys Acta 1276:161-170.
40. O'Gorman E, Beutner G, Dolder M, Koretsky AP, Brdiczka D, Wallimann T (1997) The role of creatine kinase inhibition of mitochondrial permeability transition. FEBS Lett 414:253-257.
41. Ona VO, Li M, Vonsattel JPG, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li X-J, Stieg PE, Yuan J, Penney JB, Young AB, Cha J-HJ, Friedlander RM (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399:263-267.
42. Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell Jr WO, Miller G, Tagle DA (1998) Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 20:198-202.
43. Sauter A, Rudin M (1993) Determination of creatine kinase parameters in rat brain by NMR magnetization transfer: correlation with brain function. J Biol Chem 268:13166-13171.
44. Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler Jr JF, Greenamyre JT, Snyder SH, Ross CA (1999) Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 5:1194-1198.
45. Sharp NH, Loev SJ, Schilling G, Li S-H, Li X-J, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A, Hedreen J, Sisodia S, Snyder SH, Dawson TM, Ryugo DK, Ross CA (1995) Widespread expression of the Huntington's disease gene (IT-15) protein product. Neuron 14:1065-1074.
46. Sipila I, Rapola J, Simell O, Vannas A (1981) Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. N Engl J Med 304:867-870.
47. Soboll S, Brdiczka D, Jahnke D, Schmidt A, Schlattner U, Wendt S, Wyss M, Wallimann T (1999) Octamer-dimer transitions of mitochondrial creatine kinase in heart disease. J Mol Cell Cardiol 31:857-866.
48. Stachowiak O, Dolder M, Wallimann T, Richter C (1998) Mitochondrial creatine kinase is a prime target of peroxynitrite-induced modification and inactivation. J Biol Chem 273:16694-16699.
49. 2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies. Cell 89:93-103.
50. Stockler S, Holzbach U, Hanefeld F, Marquardt I, Helms G, Requart M, Hanicke W, Frahm J (1994) Creatine deficiency in the brain: a new, treatable inborn error of metabolism. Pediatr Res 36:409-413.
51. Stockler S, Hanefeld F, Frahn J (1996) Creatine replacement therapy in quanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet 348:789-790.
52. Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, Swaroop M, Kaatz KW, Collins FS, Albin RL (1993) Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet 5:259-265.
53. Tarnopolsky M, Martin J (1999) Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 52:854-857.
54. Tarnopolsky MA, Roy BD, MacDonald JR (1997) A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 20:1502-1509.
55. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
56. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559-577.
57. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM (1992) Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J 281:21-40.
58. Wheeler VC, Auerhach W, White JK, Srinidhi J, Auerbach A, Ryan A, Duyao MP, Vrbanac V, Weaver M, Gusella JF, Joyner AL, MacDonald ME (1999) Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum Mol Genet 8:115-122.
59. Xu CJ, Klunk WE, Kanfer JN, Xiong Q, Miller G, Pettegrew JW (1996) Phosphocreatine-dependent glutamate uptake by synaptic vesicles. J Biol Chem 271:13435-13440.